Financing channel feed

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Last year
Marketing

In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Last year
Startups

At­tovia reels in $105M from crossover in­vestors to run mul­ti­ple tri­als of I&I bi­o­log­ics

Last year
Startups

Aard­vark nabs $85M to tar­get hunger, not ap­petite, as it eyes 2026 NDA fil­ing

Last year
Startups

Dan­ish biotech nabs No­vo Hold­ings sup­port in seed round for com­ple­ment plat­form

Last year

Lon­nie Moul­der's Zenas clos­es a $200M Se­ries C to broad­en lead drug's au­toim­mune po­ten­tial

Last year

Flag­ship com­mits $50M to new start­up that scours vi­ral pro­teins for new drugs

Last year
Startups

Memo Ther­a­peu­tics re­fu­els with $22M to ex­pand tri­al for in­fec­tion-fight­ing an­ti­body in kid­ney trans­plant re­cip­i­ents

Last year

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

Last year
R&D

As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Last year
Startups

As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

Last year
Pharma
Cell/Gene Tx

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

Last year
Startups
Cell/Gene Tx

Biotech vets raise $67M to de­vel­op tar­get­ed ac­ti­va­tors for can­cer

Last year

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Last year
Startups
Deals

A once-pub­lic psy­che­del­ic biotech reemerges with $103M from MPM and No­vo Hold­ings

Last year
Startups

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: Pic­tion Health rais­es $6M to cut wait times for skin con­di­tions

Last year
Health Tech

In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

Last year

Cidara buys back flu rights, sells an­ti­fun­gal and inks $240M PIPE

Last year
Deals
Pharma

En­deav­or Bio­Med­i­cines snags $132M for Phase 2 fi­bro­sis drug, ADC can­di­date

Last year
Startups

Dutch biotech at­tracts J&J sup­port for can­cer pipeline in $21M Se­ries A

Last year
R&D

Re­gen­eron’s $500M fund spot­lights cor­po­rate ven­ture’s in­flu­en­tial role in biotech

Last year
Startups
Pharma

Rube­do pulls in $40M Se­ries A to ad­vance atopic der­mati­tis can­di­date tar­get­ing ag­ing cells

Last year

Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Last year
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times